Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
Cet article analyse les raisons de la sous-estimation des effets indésirables (cardiotoxicité) associés au sunitinib dans les publications des premiers essais cliniques de cette molécule
Sunitinib (Sutent; Pfizer, New York, NY) represents one of the most successful cancer therapies, with US Food and Drug Administration (FDA) approval for three malignancies and ongoing trials in more than 30 tumor types. It also represents an instructive example revealing how adverse events can be vastly underestimated. The purpose of this article is to critically evaluate the history of the underrecognition of the cardiac toxicity of sunitinib and to propose solutions to improve adverse event monitoring for future therapies.
Journal of Clinical Oncology , résumé, 2012